Abstract: | This work reports the in vitro activity against Plasmodiumfalciparumblood forms (W2 clone, chloroquine-resistant) oftamoxifen-based compounds and their ferrocenyl (ferrocifens) and ruthenocenyl(ruthenocifens) derivatives, as well as their cytotoxicity against HepG2 humanhepatoma cells. Surprisingly with these series, results indicate that the biologicalactivity of ruthenocifens is better than that of ferrocifens and other tamoxifen-likecompounds. The synthesis of a new metal-based compound is also described. It wasshown, for the first time, that ruthenocifens are good antiplasmodial prototypes.Further studies will be conducted aiming at a better understanding of their mechanismof action and at obtaining new compounds with better therapeutic profile. |